Literature DB >> 19407476

Interferon-gamma treatment accelerates and aggravates autoimmune pancreatitis in the MRL/Mp-mouse.

Brit Fitzner1, Stephanie-Anna Holzhueter, Saleh Ibrahim, Horst Nizze, Robert Jaster.   

Abstract

BACKGROUND: T helper 1 cell-released pro-inflammatory cytokines have been implicated in the pathogenesis of autoimmune pancreatitis (AIP), but the experimental database is small. Here, we have directly tested the effects of interferon-gamma (IFN-gamma) by applying it to AIP-prone MRL/Mp mice.
METHODS: MRL/Mp-mice were treated for 4 weeks with IFN-gamma. Severity of AIP was assessed by histopathology, laboratory findings and gene expression analysis.
RESULTS: Using a histopathological score from 0 (healthy pancreas) to 4 (severe AIP), we found that IFN-gamma treatment strongly increased severity of pancreatic lesions. IFN-gamma also caused pancreatic accumulation of CD4-, CD8-, C11b- and CD138-positive cells, and enhanced pancreatic mRNA expression of interleukin (IL)-1 beta, transforming growth factor-beta and IFN-gamma itself. In the serum of IFN-gamma-treated mice, higher lipase activities but normal glucose levels were observed. DISCUSSION: IFN-gamma accelerates and aggravates AIP in MRL/Mp mice. IFN-gamma-enhanced AIP of MRL/Mp mice may serve to study pathophysiology, and to test diagnostic/therapeutic approaches. (c) 2009 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19407476     DOI: 10.1159/000199434

Source DB:  PubMed          Journal:  Pancreatology        ISSN: 1424-3903            Impact factor:   3.996


  8 in total

1.  Impact of hyperglycemia on autoimmune pancreatitis and regulatory T-cells.

Authors:  Franz-Tassilo Müller-Graff; Brit Fitzner; Robert Jaster; Brigitte Vollmar; Dietmar Zechner
Journal:  World J Gastroenterol       Date:  2018-07-28       Impact factor: 5.742

2.  Interferon-gamma increased epithelial barrier function via upregulating claudin-7 expression in human submandibular gland duct epithelium.

Authors:  Ayumi Abe; Kenichi Takano; Takashi Kojima; Kazuaki Nomura; Takuya Kakuki; Yakuto Kaneko; Motohisa Yamamoto; Hiroki Takahashi; Tetsuo Himi
Journal:  J Mol Histol       Date:  2016-03-08       Impact factor: 2.611

3.  In vitro studies implicate an imbalanced activation of dendritic cells in the pathogenesis of murine autoimmune pancreatitis.

Authors:  Luise Borufka; Erik Volmer; Sarah Müller; Robby Engelmann; Horst Nizze; Saleh Ibrahim; Robert Jaster
Journal:  Oncotarget       Date:  2016-07-12

4.  Quantitative Trait Locus Analysis Implicates CD4⁺/CD44high Memory T Cells in the Pathogenesis of Murine Autoimmune Pancreatitis.

Authors:  Julia Bischof; Sarah Müller; Luise Borufka; Farahnaz Asghari; Steffen Möller; Stephanie-Anna Holzhüter; Horst Nizze; Saleh M Ibrahim; Robert Jaster
Journal:  PLoS One       Date:  2015-09-01       Impact factor: 3.240

5.  Novel mechanism of cytokine-induced disruption of epithelial barriers: Janus kinase and protein kinase D-dependent downregulation of junction protein expression.

Authors:  Nayden G Naydenov; Somesh Baranwal; Shadab Khan; Alex Feygin; Pooja Gupta; Andrei I Ivanov
Journal:  Tissue Barriers       Date:  2013-06-03

6.  The mtDNA nt7778 G/T polymorphism augments formation of lymphocytic foci but does not aggravate cerulein-induced acute pancreatitis in mice.

Authors:  Sarah Müller; Burkhard Krüger; Falko Lange; Cristin N Bock; Horst Nizze; Änne Glass; Saleh M Ibrahim; Robert Jaster
Journal:  PLoS One       Date:  2014-07-10       Impact factor: 3.240

7.  Adoptive transfer of CD3+ T cells and CD4+ CD44high memory T cells induces autoimmune pancreatitis in MRL/MpJ mice.

Authors:  Luise Ehlers; Sarah Rohde; Saleh Ibrahim; Robert Jaster
Journal:  J Cell Mol Med       Date:  2018-01-31       Impact factor: 5.310

Review 8.  T Lymphocytes: A Promising Immunotherapeutic Target for Pancreatitis and Pancreatic Cancer?

Authors:  Qi Zhou; Xufeng Tao; Shilin Xia; Fangyue Guo; Chen Pan; Hong Xiang; Dong Shang
Journal:  Front Oncol       Date:  2020-03-24       Impact factor: 6.244

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.